NASDAQ$INCY
Incyte Corp. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Incyte reported strong Q4 2022 financial results, driven by growth in Jakafi and Opzelura sales, and provided 2023 financial guidance.
Incyte reported Q4 2022 total GAAP revenues of $926.7 million, a 7% increase compared to Q4 2021. Jakafi net revenues were $647.5 million, a 9% increase year-over-year. Opzelura net revenues reached $61.3 million, driven by strong demand in atopic dermatitis and vitiligo.
- Total FY'22 net product revenues grew 18% to $2.75 billion; total FY'22 revenues of $3.4 billion (+14% Y/Y).
- Jakafi net revenues of $647 million (+9% Y/Y) in Q4'22 and $2.41 billion (+13%) in FY'22.
- Opzelura net revenues of $61 million in Q4'22 and $129 million in FY'22, driven by strong demand in atopic dermatitis, a successful launch in vitiligo and broadening formulary access.
- Incyte granted pediatric exclusivity for Jakafi, extending patent expiry through December 2028.
Headline financials
Revenue & EPS history
Incyte · Revenue · Quarterly
$927M
Revenue by segment
Incyte · $759M total across 4 segments · Q4 2022
- Jakafi$647M+9.3%85.3%
- Opzelura$61.3M+1212.8%8.1%
- Iclusig$27.6M+2.1%3.6%
- Pemazyre$23M+17.4%3.0%
Forward guidance
Incyte provided financial guidance for 2023, which does not include revenue from any potential new product launches or the impact of any potential future strategic transactions.
Tailwinds
- Jakafi net product revenues: $2.53 - $2.63 billion
- Other Hematology/Oncology net product revenues: $215 - $225 million
- GAAP Cost of product revenues: 7 – 8% of net product revenues
- Non-GAAP Cost of product revenues: 6 – 7% of net product revenues
- GAAP Research and development expenses: $1,610 - $1,650 million
Headwinds
- Non-GAAP Research and development expenses: $1,485 - $1,520 million
- GAAP Selling, general and administrative expenses: $1,050 - $1,150 million
- Non-GAAP Selling, general and administrative expenses: $965 - $1,060 million
- Guidance does not include revenue from any potential new product launches
- Guidance does not include the impact of any potential future strategic transactions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.3%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+0.6%
Avg return
30 days after
50%
32 / 64 earnings
Positive
+18.2%
Q1 2012
Best reaction
-25.8%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | +1.2% | +0.8% | |
| Q4 2025 | -8.2% | -7.3% | -15.6% | |
| Q3 2025 | -1.6% | +0.4% | +13.5% | |
| Q1 2025 | +1.5% | +5.1% | +11.0% | |
| Q4 2024 | -7.9% | -5.0% | -8.6% | |
| Q3 2024 | +12.5% | +15.9% | +14.9% | |
| Q2 2024 | -5.1% | -6.0% | -3.9% | |
| Q1 2024 | +0.7% | +2.3% | +9.0% | |
| Q4 2023 | +0.1% | +0.2% | +1.2% | |
| Q3 2023 | +4.2% | +5.2% | +4.2% | |
| Q2 2023 | +3.1% | -0.1% | +1.3% | |
| Q1 2023 | -9.7% | -11.7% | -18.4% | |
| Q4 2022 | -4.6% | -6.0% | -13.6% | |
| Q3 2022 | +3.8% | +4.0% | +8.5% | |
| Q2 2022 | -6.3% | -6.8% | -7.8% | |
| Q1 2022 | +6.1% | -1.1% | -1.9% | |
| Q4 2021 | -6.9% | -9.0% | +0.2% | |
| Q3 2021 | -3.7% | -2.1% | -3.9% | |
| Q2 2021 | -1.4% | -2.8% | -1.6% | |
| Q1 2021 | -5.0% | -3.3% | -3.1% | |
| Q4 2020 | -9.0% | -9.9% | -15.1% | |
| Q3 2020 | -8.8% | -8.9% | -8.8% | |
| Q2 2020 | -4.1% | -4.8% | -10.0% | |
| Q1 2020 | -4.9% | -5.0% | -7.1% | |
| Q4 2019 | +3.5% | +4.6% | -2.6% | |
| Q3 2019 | +4.8% | +4.7% | +17.9% | |
| Q2 2019 | +5.8% | +4.0% | +2.7% | |
| Q1 2019 | +6.1% | +11.7% | +5.9% | |
| Q4 2018 | +3.8% | +3.7% | +4.6% | |
| Q3 2018 | +2.4% | +6.5% | +2.3% | |
| Q2 2018 | -4.4% | -8.1% | +7.4% | |
| Q1 2018 | -1.4% | +0.3% | +10.2% | |
| Q4 2017 | -2.4% | -3.0% | +2.1% | |
| Q3 2017 | -5.5% | -8.0% | -13.3% | |
| Q2 2017 | -5.7% | -3.4% | +3.1% | |
| Q1 2017 | -0.6% | -2.8% | +6.7% | |
| Q4 2016 | -0.2% | -0.5% | +22.5% | |
| Q3 2016 | +0.2% | +0.7% | +14.9% | |
| Q2 2016 | -5.2% | -7.9% | -7.4% | |
| Q1 2016 | +4.0% | — | — | |
| Q4 2015 | -5.5% | — | — | |
| Q3 2015 | -2.9% | — | — | |
| Q2 2015 | +6.7% | — | — | |
| Q1 2015 | -3.3% | — | — | |
| Q4 2014 | -0.0% | — | — | |
| Q3 2014 | +15.9% | — | — | |
| Q2 2014 | -4.9% | — | — | |
| Q1 2014 | +6.3% | — | — | |
| Q4 2013 | +0.2% | — | — | |
| Q3 2013 | +4.7% | — | — | |
| Q2 2013 | +14.7% | — | — | |
| Q1 2013 | +3.3% | — | — | |
| Q4 2012 | +18.0% | — | — | |
| Q3 2012 | +6.8% | — | — | |
| Q2 2012 | -25.8% | — | — | |
| Q1 2012 | +18.2% | — | — | |
| Q4 2011 | +1.7% | — | — | |
| Q3 2010 | +0.9% | — | — | |
| Q3 2011 | +0.9% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2010 | +6.0% | — | — | |
| Q1 2010 | +6.0% | — | — | |
| Q1 2011 | +6.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro